FDA Slammed for Calling BPA Safe

[amazon_link asins=’B01KS5H0S6,B000ZHS92O,B0128YT76S,B017M0EK5Q,B00A1LUFK8,B00VWJHFTM,B019ERIYEI,B01M62G6T4′ template=’ProductCarousel’ store=’finmeacur-20′ marketplace=’US’ link_id=’de7f7f88-5115-11e7-89d9-b977b82fee9e’][amazon_link asins=’B06Y3TFWQT,B010A5JP5K,B01N9QRQ2H,B01L9YOZ60,B06ZZ57DSS,B01B3DMTQA,B01M14V6VE,B017NWB092,B01IHOHYUY’ template=’ProductCarousel’ store=’finmeacur-20′ marketplace=’US’ link_id=’acb5d4c8-5115-11e7-b8b2-71b3e2178d2f’]

In a highly critical report, a panel of scientists from government and academia said when the FDA completed a draft risk assessment of bisphenol A (BPA) last month, they did not take into consideration numerous studies that have linked the chemical to prostate cancer, diabetes and other health problems.

The scientists took the FDA to task for basing its safety decision on three industry-funded studies.

The report was written by a subcommittee panel of the FDA’s outside science board, experts who advise the FDA on complex issues. The panel concluded that the FDA’s margin of safety is “inadequate.”

The panel said the FDA also didn’t use enough infant formula samples and didn’t adequately account for variations among the samples.

Studies the FDA did not consider when making their assessment suggest that BPA could pose harm to children at levels at least 10 times lower than the amount the agency called safe. Another government agency, the National Toxicology Program, concluded that there is “some concern” that BPA alters development of the brain, prostate and behavior in children and fetuses.